Relmada Therapeutics (RLMD) Tops Q2 EPS by 6c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.84), $0.06 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c